PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26742006-0	2016	Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer.	Tamoxifen	49-58	androgen receptor	Homo sapiens	0-17	
26742006-2	2016	In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation.	Tamoxifen	48-57	androgen receptor	Homo sapiens	30-32	
26742006-3	2016	PURPOSE: To investigate the tamoxifen predictive relevance of the AR protein expression in breast cancer.	Tamoxifen	28-37	androgen receptor	Homo sapiens	66-68	
26742006-7	2016	RESULTS: In patients with oestrogen receptor (ER)-negative tumours, expression of AR predicted decreased recurrence rate with tamoxifen (hazard ratio (HR)=0.34; 95% confidence interval (CI)=0.14-0.81; P=0.015), whereas the opposite was seen in the AR- group (HR=2.92; 95% CI=1.16-7.31; P=0.022).	Tamoxifen	126-135	androgen receptor	Homo sapiens	82-84	
26742006-9	2016	Patients with triple-negative and AR+ tumours benefitted from tamoxifen treatment (HR=0.12; 95% CI=0.014-0.95 P=0.044), whereas patients with AR- tumours had worse outcome when treated with tamoxifen (HR=3.98; 95% CI=1.32-12.03; P=0.014).	Tamoxifen	62-71	androgen receptor	Homo sapiens	34-36	
26742006-12	2016	CONCLUSIONS: AR can predict tamoxifen treatment benefit in patients with ER- tumours and triple-negative breast cancer.	Tamoxifen	28-37	androgen receptor	Homo sapiens	13-15